Novo Nordisk faces AI shift and first G7 generic semaglutide test

• Novo Nordisk has entered into a partnership with OpenAI to apply advanced AI tools across drug discovery and development.
• Health Canada has approved a generic version of semaglutide, the active ingredient in Ozempic, as a diabetes treatment.
• This is the first approval of generic GLP-1 semaglutide in a G7 country and will introduce a new competitor to Ozempic in Canada.

Novo Nordisk, trading as CPSE:NOVO B, is at the center of two major changes that directly impact its core GLP-1 franchise and long-term research plans. The stock is valued at DKK 260.65, with a return of 12.8% over the past 30 days and a return of 4.7% over the past week, but over a longer period of time, it is down 21.1% year-to-date and down 37.3% over the past year, indicating poor performance. As a result of these developments, companies that have emerged with new competitiveness and technological capabilities are already under intense scrutiny.

For investors, the partnership with OpenAI raises questions about how quickly AI can impact discovery timelines and R&D productivity, while Health Canada’s semaglutide decision highlights the risk of increasing general pressure on GLP-1 returns in developed markets. Taken together, these developments are likely to shape thinking about Novo Nordisk’s future product mix, pricing power and capital allocation priorities in the coming years.

Add to your Watchlist or Portfolio to stay up to date with the most important news stories about Novo Nordisk. Or explore our community and discover new perspectives on Novo Nordisk.

Four things that are right for Novo Nordisk that aren’t covered in this headline.

quick evaluation

• ✅ Price and analyst targets: The stock price is DKK 260.65, about 15% below the analyst target of DKK 307.67.
• ✅ Simply Wall Street Ratings: Described as trading 66.1% below estimated fair value, suggesting a large valuation gap.
• ✅ Recent momentum: Up 12.8% in the past 30 days, indicating positive short-term price momentum.

There’s only one way to know when is the right time to buy, sell or hold Novo Nordisk. For our latest analysis of Novo Nordisk’s fair value, check out Simply Wall St’s company report.

Key considerations

• 📊 OpenAI partnerships speak directly to productivity in drug discovery, which can be critical to how we think about R&D efficiency and future pipelines.
• 📊 With Canada’s first G7 generic semaglutide approval, stay tuned for comments on GLP-1 pricing, volume trends, and market share in our earnings update.
• ⚠️ With 5 flagged risks, including 1 material, it will be important to weigh the current valuation discount against potential general pressures.

dig deeper

For the complete picture, including additional risks and rewards, check out our complete analysis of Novo Nordisk. Alternatively, you can check out Novo Nordisk’s community page to see how other investors think this latest news will impact the company’s story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodologies, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.